{
    "clinical_study": {
        "@rank": "154657", 
        "arm_group": [
            {
                "arm_group_label": "D2 surgery", 
                "arm_group_type": "Other", 
                "description": "D2 surgery(No.1\u3001No.3\u3001No.4sb\u3001No.4d\u3001No.5\u3001No.6\u3001No.7 and No.8a\u3001No.9\u3001No.11p\u3001No.12a lymph node)"
            }, 
            {
                "arm_group_label": "D2+ surgery", 
                "arm_group_type": "Experimental", 
                "description": "D2+ surgery(D2+8p\u300112b\u300113\u300114v lymph node)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and the effect of D2 and D2+ radical\n      surgery for the treatment of advanced distal gastric cancer."
        }, 
        "brief_title": "D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "To evaluate the safety and the disease-free survival time(DFS) and overall survival time(OS)\n      of D2 and D2+ radical surgery for the treatment of advanced distal gastric cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female aged 18 to 70 years old.\n\n          -  The preoperative evaluation: distal gastric cancer patients, \u2265 T2 or N +; or staging\n             II, IIIA, IIIB.\n\n          -  Karnofsky score \u2265 70, life expectancy > 6 months.\n\n          -  Endoscopic biopsy diagnosis of gastric cancer, excluding non-Hodgkin's lymphoma,\n             leiomyosarcoma and other mesenchymal tumors.\n\n          -  the blood and biochemical indicators of the subjects must meet the following\n             criteria: Hb \u2265 9 g / dl; WBC \u2265 4,000 / mm3, \u2264 12000 / mm3; PLT \u2265 100,000/mm3;\n\n          -  GOT, GPT within twice the institutional limit,serum total bilirubin < 1.5 times the\n             upper limit of normal, serum creatinine< 1.25 times the upper limit of normal\n\n          -  have not received prior chemotherapy, radiotherapy and biological therapy. signed\n             informed consent.\n\n          -  must accept the standard D2 or D2 + radical gastrectomy.\n\n          -  with good compliance.\n\n        Exclusion Criteria:\n\n          -  pregnancy, breast-feeding women.\n\n          -  allergy with chemotherapy drugs or metabolic disorder.\n\n          -  the history of organ transplants (including bone marrow transplantation and\n             autologous peripheral stem cell transplantation).\n\n          -  had long received systemic steroid treatment (Note: short-term users of withdrawal >\n             2 weeks can be selected.)\n\n          -  The existence of the peripheral nervous system disorders or significant neurological\n             disorders and a history of central nervous system disorders.\n\n          -  patients with severe infection requires treatment.\n\n          -  patients associated with dysphagia, active peptic ulcer, incompleteness intestinal\n             obstruction, active gastrointestinal bleeding, perforation.\n\n        severe liver disease (such as cirrhosis), kidney disease, respiratory disease or\n        uncontrollable diabetes.\n\n          -  with other malignancies which were not cured.\n\n          -  EKG abnormalities or heart disease with apparent clinical symptoms, including\n             congestive heart failure, coronary heart disease with symptoms, uncontrollable\n             arrhythmia, hypertension, and heart attack within 12 months or III or IV grade\n             myocardial infarction. Coronary heart disease with symptoms, uncontrollable\n             arrhythmia, hypertension, and heart attack within 12 months or III or IV grade\n             myocardial infarction."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836991", 
            "org_study_id": "RS-ADGC"
        }, 
        "intervention": {
            "arm_group_label": [
                "D2 surgery", 
                "D2+ surgery"
            ], 
            "intervention_name": "surgery", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "gastric cancer", 
            "surgery", 
            "surgery safety", 
            "effect"
        ], 
        "lastchanged_date": "April 22, 2013", 
        "location": {
            "contact": {
                "email": "ypfzmu@163.com", 
                "last_name": "xiangdong Cheng", 
                "phone": "+86 571 88122516"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou,", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310022"
                }, 
                "name": "Zhejiang Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "xiangdong Cheng", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2 Study of D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer", 
        "overall_contact": {
            "email": "ypfzmu@163.com", 
            "last_name": "xiangdong Cheng, MD", 
            "phone": "+86 571 88122516"
        }, 
        "overall_official": {
            "affiliation": "Zhejiang Cancer Hospital", 
            "last_name": "xiangdong Cheng", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "the disease-free survival time", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "the overall survival time", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836991"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Zhejiang Cancer Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}